Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype
- PMID:18773455
- DOI: 10.1002/cyto.a.20633
Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype
Abstract
Side population (SP) analyses and CD133 expression have identified cells with stem-like potential in normal and cancerous tissue. Whether stem-like cells exist in cancer cell lines is hotly debated. We have interrogated the DAOY medulloblastoma cell line with respect to stem-like potential. Vital staining for Hoechst 33342 efflux capacity and CD133 immunophenotyping were performed on DAOY cells to assess the presence of the SP and the CD133 stem cell markers, respectively. SP/non-SP and CD133(+)/CD133(-) DAOY cells were sorted into separate fractions for limiting dilution analysis (tumor sphere assay) and asymmetric division assessment. SP/non-SP cells were also sorted separately for viability (XTT assay), cell size, cell cycle status, and proliferative capacity (carboxyfluorescein succinimidyl ester (CFSE)) evaluation. A minor proportion of cells displayed either the SP or the CD133(+) phenotypes. CD133 expression mapped to both the SP and non-SP compartments, with CD133(+) cells being enriched almost fourfold within the non-SP gate. The SP, non-SP, CD133(+), and CD133(-) fractions were all capable of reconstituting the original parental DAOY population. Slight clonogenic enrichment was observed in only the SP fraction; however, both CD133(+) and CD133(-) cells displayed equivalent stem cell-like frequencies. SP cells were resistant to Hoechst 33342-mediated toxicity relative to the parental population and differed from the non-SP cells with respect to increased cell size, decreased S-phase, and slightly decreased proliferative capacity. The multiparametric strategy described in this study revealed that the SP and CD133(+) subset may be two independent compartments. Our results highlight the need for new reliable specific cancer stem cell marker(s) as Hoechst 33342 efflux and CD133 expression might not be suitable for selectively isolating cancer stem-like cells from cell lines, as shown for the DAOY cells. As such, care must be used in interpreting therapeutic studies targeting the stem cell compartment of cancer cell lines.
Copyright 2008 International Society for Advancement of Cytometry.
Similar articles
- Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype.Annabi B, Rojas-Sutterlin S, Laflamme C, Lachambre MP, Rolland Y, Sartelet H, Béliveau R.Annabi B, et al.Mol Cancer Res. 2008 Jun;6(6):907-16. doi: 10.1158/1541-7786.MCR-07-2184.Mol Cancer Res. 2008.PMID:18567795
- [Isolation and in vivo tumorigenicity assay of CD133+ side population cells from laryngeal cancer cell line].Wu CP, Zhou L, Xie M, Tao L, Zhang M, Tian J.Wu CP, et al.Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012 Mar;47(3):223-7.Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012.PMID:22805024Chinese.
- Members of the low-density lipoprotein receptor-related proteins provide a differential molecular signature between parental and CD133+ DAOY medulloblastoma cells.Annabi B, Doumit J, Plouffe K, Laflamme C, Lord-Dufour S, Béliveau R.Annabi B, et al.Mol Carcinog. 2010 Jul;49(7):710-7. doi: 10.1002/mc.20645.Mol Carcinog. 2010.PMID:20564348
- Melanoma stem cells: the dark seed of melanoma.Zabierowski SE, Herlyn M.Zabierowski SE, et al.J Clin Oncol. 2008 Jun 10;26(17):2890-4. doi: 10.1200/JCO.2007.15.5465.J Clin Oncol. 2008.PMID:18539969Review.
- How powerful is CD133 as a cancer stem cell marker in brain tumors?Cheng JX, Liu BL, Zhang X.Cheng JX, et al.Cancer Treat Rev. 2009 Aug;35(5):403-8. doi: 10.1016/j.ctrv.2009.03.002. Epub 2009 Apr 14.Cancer Treat Rev. 2009.PMID:19369008Review.
Cited by
- Characterisation of normal and cancer stem cells: one experimental paradigm for two kinds of stem cells.Mayol JF, Loeuillet C, Hérodin F, Wion D.Mayol JF, et al.Bioessays. 2009 Sep;31(9):993-1001. doi: 10.1002/bies.200900041.Bioessays. 2009.PMID:19644922Free PMC article.
- Screening of aptamers specific to colorectal cancer cells and stem cells by utilizing On-chip Cell-SELEX.Hung LY, Wang CH, Che YJ, Fu CY, Chang HY, Wang K, Lee GB.Hung LY, et al.Sci Rep. 2015 May 22;5:10326. doi: 10.1038/srep10326.Sci Rep. 2015.PMID:25999049Free PMC article.
- Gene expression of growth signaling pathways is up-regulated in CD133-positive medulloblastoma cells.Gu C, Yokota N, Gao Y, Yamamoto J, Tokuyama T, Namba H.Gu C, et al.Oncol Lett. 2011 Mar;2(2):357-361. doi: 10.3892/ol.2011.235. Epub 2011 Jan 14.Oncol Lett. 2011.PMID:22866088Free PMC article.
- Glioblastoma formation from cell population depleted of Prominin1-expressing cells.Nishide K, Nakatani Y, Kiyonari H, Kondo T.Nishide K, et al.PLoS One. 2009 Aug 31;4(8):e6869. doi: 10.1371/journal.pone.0006869.PLoS One. 2009.PMID:19718438Free PMC article.
- Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting.Vieira de Castro J, Gonçalves CS, Hormigo A, Costa BM.Vieira de Castro J, et al.Int J Mol Sci. 2020 Jul 25;21(15):5278. doi: 10.3390/ijms21155278.Int J Mol Sci. 2020.PMID:32722427Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Research Materials